Malaria medicines: A glass half full?

Nature Reviews Drug Discovery

Volumn 14, Issue 6, 2015, Pages 424-442

  Wells, Timothy N C ^a   Van Huijsduijnen, Rob Hooft ^a   Van Voorhis, Wesley C ^a,b  

^a Switzerland   (Switzerland)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT; AQ 13; ARTEFENOMEL; ARTEMISIN DERIVATIVE; ARTEMISONE; ARTEROLANE; ARTEROLANE PLUS PIPERAQUINE; ARTESUNATE; CIPARGAMIN; DIHYDROOROTATE DEHYDROGENASE INHIBITOR; DSM 265; FERROQUINE; KAF 156; MALARIA VACCINE; MMV 390048; PYRIMETHAMINE PLUS SULFADOXINE; TAFENOQUINE; UNCLASSIFIED DRUG;

ANTIMALARIAL DRUG RESISTANCE; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; DRUG CLASSIFICATION; DRUG COST; DRUG DESIGN; DRUG TARGETING; HUMAN; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MORTALITY; NONHUMAN; PARASITE TRANSMISSION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PHENOTYPE; PLASMODIUM OVALE; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; RECURRENT INFECTION; REPRODUCTIVE TOXICITY; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION; ANIMAL; DRUG DEVELOPMENT; HEALTH; TRENDS;

ANIMALS; ANTIMALARIALS; DRUG DISCOVERY; GLOBAL HEALTH; HUMANS; MALARIA;

EID: 84930381560     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4573     Document Type: Review

References (160)

1. Whitfield J. Portrait of a serial killer: a roundup of the history and biology of the malaria parasite. Nature http//dx.doi.org/10.1038/news021001-6 (2002
2. World Health Organization. World Malaria Report (WHO, 2014
3. Sachs J. & Malaney P. The economic and social burden of malaria. Nature 415, 680-685 (2002
4. Sicuri E., Vieta A., Lindner L., Constenla D. & Sauboin C. The economic costs of malaria in children in three sub-Saharan countries: Ghana, Tanzania and Kenya. Malar. J. 12, 307 (2013
5. Wells T. N., Alonso P. L. & Gutteridge W. E. New medicines to improve control and contribute to the eradication of malaria. Nature Rev. Drug Discov. 8, 879-891 (2009
6. Anthony M. P., Burrows J. N., Duparc S., Moehrle J. & Wells T. N. C. The global pipeline of new medicines for the control and elimination of malaria. Malar. J. 11, 316 (2012
7. Biamonte M. A., Wanner J. & Le Roch K. G. Recent advances in malaria drug discovery. Bioorg. Med. Chem. Lett. 23, 2829-2843 (2013
8. Alonso P. L., et al. A research agenda to underpin malaria eradication. PLoS Med. 8, e1000406 (2011
9. MalERA Consultative Group on Drugs. A research agenda for malaria eradication: drugs. PLoS Med. 8, e1000402 (2011
10. Burrows J. N., Hooft van Huijsduijnen R., Möhrle J. J., Oeuvray C. & Wells T. N. C. Designing the next generation of medicines for malaria control and eradication. Malar. J. 12, 187 (2013
11. Engwerda C. R., Minigo G., Amante F. H. & McCarthy J. S. Experimentally induced blood stage malaria infection as a tool for clinical research. Trends Parasitol. 28, 515-521 (2012
12. Bosman A. & Mendis K. N. A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am. J. Trop. Med. Hyg. 77 (Suppl. 6), 193-197 (2007
13. Noedl H., et al. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359, 2619-2620 (2008
14. Dondorp A. M., et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361, 455-467 (2009
15. Phyo A. P., et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 379, 1960-1966 (2012
16. Ariey F., et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505, 50-55 (2014
17. Miotto O., et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nature Genet. 47, 226-234 (2015
18. Straimer J., et al. K13 propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science 347, 428-431 (2014
19. Jong-wook L. Global health improvement and WHO: shaping the future. Lancet 362, 2083-2088 (2003
20. Owens S. Malaria and the millennium development goals. Arch. Dis. Child. 100 (Suppl. 1), 53-56 (2015
21. Roll Back Malaria Partnership. Key facts, figures and strategies. Roll Back Malaria [online], http//www.rollbackmalaria.org/microsites/gmap/GMAP-Advocacy-ENG-web.pdf (2008
22. Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst. Rev. 2004, CD000363 (2004
23. Cohen J. M., et al. Malaria resurgence: a systematic review and assessment of its causes. Malar. J. 11, 122 (2012
24. Roll Back Malaria Partnership. The global malaria action plan for a malaria-free world. Roll Back Malaria [online], http//archiverbm.rollbackmalaria.org/gmap/gmap.pdf (2008
25. Toe K. H., et al. Increased pyrethroid resistance in malaria vectors and decreased bed net effectiveness, Burkina Faso. Emerg. Infect. Dis. 20, 1691-1696 (2014
26. Ashley E. A., et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 371, 411-423 (2014
27. Bethell D., et al. Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. PLoS ONE 6, e19283 (2011
28. Gatton M. L., Martin L. B. & Cheng Q. Evolution of resistance to sulfadoxine-pyrimethamine in Plasmodium falciparum. Antimicrob. Agents Chemother. 48, 2116-2123 (2004
29. Vinayak S., et al. Origin and evolution of sulfadoxine resistant Plasmodium falciparum. PLoS Pathog. 6, e1000830 (2010
30. Harrington W. E., Mutabingwa T. K., Kabyemela E., Fried M. & Duffy P. E. Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Clin. Infect. Dis. 53, 224-230 (2011
31. Steketee R. W. & ter Kuile F. Single low-dose primaquine to reduce malaria transmission. Lancet Infect. Dis. 14, 91-92 (2014
32. Baird J. K. Neglect of Plasmodium vivax malaria. Trends Parasitol. 23, 533-539 (2007
33. Bolchoz L. J., Budinsky R. A., McMillan D. C. & Jollow D. J. Primaquine-induced hemolytic anemia: formation and hemotoxicity of the arylhydroxylamine metabolite 6 methoxy 8 hydroxylaminoquinoline. J. Pharmacol. Exp. Ther. 297, 509-515 (2001
34. Llanos-Cuentas A., et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 383, 1049-1058 (2014
35. Price R. N. & Nosten F. Single-dose radical cure of Plasmodium vivax: a step closer. Lancet 383, 1020-1021 (2014
36. Gesase S., et al. High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in Northern Tanzania and the emergence of dhps resistance mutation at codon 581. PLoS ONE 4, e4569 (2009
37. Adam I., Khamis A. H. & Elbashir M. I. Prevalence and risk factors for Plasmodium falciparum malaria in pregnant women of eastern Sudan. Malar. J. 4, 18 (2005
38. Masaninga F., et al. Review of the malaria epidemiology and trends in Zambia. Asian Pac. J. Trop. Biomed. 3, 89-94 (2013
39. Biot C., et al. The antimalarial ferroquine: from bench to clinic. Parasite 18, 207-214 (2011
40. Supan C., et al. Pharmacokinetics of ferroquine, a novel 4 aminoquinoline, in asymptomatic carriers of Plasmodium falciparum infections. Antimicrob. Agents Chemother. 56, 3165-3173 (2012
41. Chavain N., et al. Investigation of the redox behavior of ferroquine, a new antimalarial. Mol. Pharm. 5, 710-716 (2008
42. Zhu C. & Cook S. P. A concise synthesis of (+)-artemisinin. J. Am. Chem. Soc. 134, 13577-13579 (2012
43. Kopetzki D., Levesque F. & Seeberger P. H. A continuous-flow process for the synthesis of artemisinin. Chemistry 19, 5450-5456 (2013
44. Levesque F. & Seeberger P. H. Continuous-flow synthesis of the anti-malaria drug artemisinin. Angew. Chem. Int. Ed. Engl. 51, 1706-1709 (2012
45. Valecha N., et al. Arterolane maleate plus piperaquine phosphate for treatment of uncomplicated Plasmodium falciparum malaria: a comparative, multicenter, randomized clinical trial. Clin. Infect. Dis. 55, 663-671 (2012
46. Noedl H. The need for new antimalarial drugs less prone to resistance. Curr. Pharm. Design 19, 266-269 (2013
47. Dondorp A. M., et al. Artemisinin resistance: current status and scenarios for containment. Nature Rev. Microbiol. 8, 272-280 (2010
48. Witkowski B., et al. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob. Agents Chemother. 57, 914-923 (2013
49. White T. E., Bushdid P. B., Ritter S., Laffan S. B. & Clark R. L. Artesunate-induced depletion of embryonic erythroblasts precedes embryolethality and teratogenicity in vivo. Birth Defects Res. B Dev. Reprod. Toxicol. 77, 413-429 (2006
50. Nagelschmitz J., et al. First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone. Antimicrob. Agents Chemother. 52, 3085-3091 (2008
51. O'Neill P. M., et al. Identification of a 1,2,4,5 tetraoxane antimalarial drug-development candidate (RKA 182) with superior properties to the semisynthetic artemisinins. Angew. Chem. Int. Ed. Engl. 49, 5693-5697 (2010
52. Mzayek F., et al. Randomized dose-ranging controlled trial of AQ 13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin. Trials 2, e6 (2007
53. Thelingwani R., Bonn B., Chibale K. & Masimirembwa C. Physicochemical and drug metabolism characterization of a series of 4 aminoquinoline 3 hydroxypyridin 4 one hybrid molecules with antimalarial activity. Expert Opin. Drug Metab. Toxicol. 10, 1313-1324 (2014
54. van Noord C., Eijgelsheim M. & Stricker B. H. Drug-and non-drug-associated QT interval prolongation. Br. J. Clin. Pharmacol. 70, 16-23 (2010
55. Zani B., Gathu M., Donegan S., Olliaro P. L. & Sinclair D. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst. Rev. 1, CD010927 (2014
56. Wells T. N. C. Is the tide turning for new malaria medicines?. Science 329, 1153-1154 (2010
57. Coteron J. M., et al. Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. J. Med. Chem. 54, 5540-5561 (2011
58. Deng X., et al. Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds. J. Biol. Chem. 284, 26999-27009 (2009
59. McCarthy J. S., et al. A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs. PLoS ONE 6, e21914 (2011
60. Meister S., et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 334, 1372-1377 (2011
61. Gamo F. J., et al. Thousands of chemical starting points for antimalarial lead identification. Nature 465, 305-310 (2010
62. Guiguemde W. A., et al. Chemical genetics of Plasmodium falciparum. Nature 465, 311-315 (2010
63. Spangenberg T., et al. The open access malaria box: a drug discovery catalyst for neglected diseases. LoS ONE 8, e62906 (2013
64. Avery V. M., et al. Screening and hit evaluation of a chemical library against blood-stage Plasmodium falciparum. Malar. J. 13, 190 (2014
65. Rottmann M., et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 329, 1175-1180 (2010
66. Yeung B. K., et al. Spirotetrahydro β-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. J. Med. Chem. 53, 5155-5164 (2010
67. Spillman N. J., et al. Na+ regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. Cell Host Microbe 13, 227-237 (2013
68. Krishna S., et al. Expression and functional characterization of a Plasmodium falciparum Ca2+-ATPase (PfATP4) belonging to a subclass unique to apicomplexan organisms. J. Biol. Chem. 276, 10782-10787 (2001
69. Leong F. J., et al. A first in human randomized, double-blind, placebo-controlled, single-and multiple-ascending oral dose study of novel antimalarial spiroindolone KAE609 (cipargamin), to assess the safety, tolerability and pharmacokinetics in healthy adult volunteers. Antimicrob. Agents Chemother. 58, 6209-6214 (2014
70. White N. J., et al. Spiroindolone KAE609 for falciparum and vivax malaria. N. Engl. J. Med. 371, 403-410 (2014
71. Cully M. Trial watch: next-generation antimalarial from phenotypic screen shows clinical promise. Nature Rev. Drug Discov. 13, 717 (2014
72. Flannery E. L., Chatterjee A. K. & Winzeler E. A. Antimalarial drug discovery -approaches and progress towards new medicines. Nature Rev. Microbiol. 11, 849-862 (2013
73. Das S., et al. in The Annual Symposium of the Institute for Molecular Medicine & Infectious Disease Abstract B11, 46 (Drexel Univ. College of Medicine, 2014
74. Vaidya A. B., et al. Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum. Nature Commun. 5, 5521 (2014
75. Jimenez-Diaz M. B., et al. SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc. Natl Acad. Sci. USA 111, E5455-E5462 (2014
76. Lehane A. M., Ridgway M. C., Baker E. & Kirk K. Diverse chemotypes disrupt ion homeostasis in the malaria parasite. Mol. Microbiol. 94, 327-339 (2014
77. Younis Y., et al. 3,5 diaryl 2 aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J. Med. Chem. 55, 3479-3487 (2012
78. Ghidelli-Disse S., et al. Identification of Plasmodium PI4 kinase as target of MMV390048 by chemoproteomics. Malar. J. 13, S21 (2014
79. McNamara C. W., et al. Targeting Plasmodium PI(4)K to eliminate malaria. Nature 504, 248-253 (2013
80. Overington J. P., Al Lazikani B. & Hopkins A. L. How many drug targets are there?. Nature Rev. Drug Discov. 5, 993-996 (2006
81. Gileadi O., et al. The scientific impact of the Structural Genomics Consortium: a protein family and ligand-centered approach to medically-relevant human proteins. J. Struct. Funct. Genom. 8, 107-119 (2007
82. Mullard A. European lead factory opens for business. Nature Rev. Drug Discov. 12, 173-175 (2013
83. Carroll J. Will combinatorial chemistry keep its promise?. Biotechnol. Healthc. 2, 26-32 (2005
84. Geysen H. M., Schoenen F., Wagner D. & Wagner R. Combinatorial compound libraries for drug discovery: an ongoing challenge. Nature Rev. Drug Discov. 2, 222-230 (2003
85. Wells T. N. Natural products as starting points for future anti-malarial therapies: going back to our roots?. Malar. J. 10 (Suppl. 1), 3 (2011
86. Wells T. N. Discovering and developing new medicines for malaria control and elimination. Infect. Disord. Drug Targets 13, 292-302 (2013
87. Holmes D. The GHIT fund shows its cards. Nature Rev. Drug Discov. 12, 894 (2013
88. Slingsby B. T. & Kurokawa K. The Global Health Innovative Technology (GHIT) Fund: financing medical innovations for neglected populations. Lancet Glob. Health 1, e184-e185 (2013
89. Zhang Y. K., et al. Synthesis and structure-activity relationships of novel benzoxaboroles as a new class of antimalarial agents. Bioorg. Med. Chem. Lett. 21, 644-651 (2011
90. Duffy S. & Avery V. M. Identification of inhibitors of Plasmodium falciparum gametocyte development. Malar. J. 12, 408 (2013
91. Dembele L., et al. Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures. Nature Med. 20, 307-312 (2014
92. March S., et al. A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. Cell Host Microbe 14, 104-115 (2013
93. Hayden F. G. Experimental human influenza: observations from studies of influenza antivirals. Antivir. Ther. 17, 133-141 (2012
94. Atmar R. L., et al. Norwalk virus shedding after experimental human infection. Emerg. Infect. Dis. 14, 1553-1557 (2008
95. Cordey S., et al. Rhinovirus genome evolution during experimental human infection. PLoS ONE 5, e10588 (2010
96. Spring M., Polhemus M. & Ockenhouse C. Controlled human malaria infection. J. Infect. Dis. 209 (Suppl. 2), 40-45 (2014
97. Epstein J. E., et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 334, 475-480 (2011
98. Bousema T., et al. Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers. PLoS ONE 7, e42821 (2012
99. Price R. N., Baird J. K. & Hay S. I. The Epidemiology of Plasmodium vivax: History, Hiatus and Hubris (eds. Rollinson D. & Stothard R.) (Elsevier, 2012
100. Campbell M. C. & Tishkoff S. A. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu. Rev. Genom. Hum. Genet. 9, 403-433 (2008
101. Ma Q. & Lu A. Y. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol. Rev. 63, 437-459 (2011
102. Pang T. Impact of pharmacogenomics on neglected diseases of the developing world. Am. J. Pharmacogenomics 3, 393-398 (2003
103. Schuhmacher A., Germann P. G., Trill H. & Gassmann O. Models for open innovation in the pharmaceutical industry. Drug Discov. Today 18, 1133-1137 (2013
104. Murphy R. C., et al. Discovery of potent and selective inhibitors of calcium-dependent protein kinase 1 (CDPK1) from C. parvum and T. gondii. ACS Med. Chem. Lett. 1, 331-335 (2010
105. Bessoff K., et al. Identification of Cryptosporidium parvum active chemical series by repurposing the open access malaria box. Antimicrob. Agents Chemother. 58, 2731-2739 (2014
106. Boyom F. F., et al. Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica. Antimicrob. Agents Chemother. 58, 5848-5854 (2014
107. Aleman Resto Y. & Fernandez Robledo J. A. Identification of MMV malaria box inhibitors of Perkinsus marinus using an ATP-based bioluminescence assay. PLoS ONE 9, e111051 (2014
108. Ingram-Sieber K., et al. Orally active antischistosomal early leads identified from the open access malaria box. PLoS Negl. Trop. Dis. 8, e2610 (2014
109. Doolan D. L., Dobano C. & Baird J. K. Acquired immunity to malaria. Clin. Microbiol. Rev. 22, 13-36 (2009
110. Rappuoli R. & Aderem A. A. 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 473, 463-469 (2011
111. RTS, S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 11, e1001685 (2014
112. World Health Organization. Global malaria vaccine pipeline. WHO [online], http//www.who.int/vaccine- research/links/Rainbow/en/index.html (2014
113. Seder R. A., et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341, 1359-1365 (2013
114. McAllister M. M. Successful vaccines for naturally occurring protozoal diseases of animals should guide human vaccine research. A review of protozoal vaccines and their designs. Parasitology 141, 624-640 (2014
115. Petrovsky N. & Aguilar J. C. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 82, 488-496 (2004
116. Alving C. R., Peachman K. K., Rao M. & Reed S. G. Adjuvants for human vaccines. Curr. Opin. Immunol. 24, 310-315 (2012
117. Kyes S. A., Kraemer S. M. & Smith J. D. Antigenic variation in Plasmodium falciparum: gene organization and regulation of the var multigene family. Eukaryot. Cell 6, 1511-1520 (2007
118. Kyes S., et al. Plasmodium falciparum var gene expression is developmentally controlled at the level of RNA polymerase II mediated transcription initiation. Mol. Microbiol. 63, 1237-1247 (2007
119. Stockdale C., Swiderski M. R., Barry J. D. & McCulloch R. Antigenic variation in Trypanosoma brucei: joining the DOTs. PLoS Biol. 6, e185 (2008
120. Ubben D. & Poll E. M. MMV in partnership: the Eurartesim® experience. Malar. J. 12, 211 (2013
121. Dondorp A., et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366, 717-725 (2005
122. Dondorp A. M., et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376, 1647-1657 (2010
123. Ritchie E. C., Block J. & Nevin R. L. Psychiatric side effects of mefloquine: applications to forensic psychiatry. J. Am. Acad. Psychiatry Law 41, 224-235 (2013
124. Tansley R., et al. A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of single enantiomer (+)-mefloquine compared with racemic mefloquine in healthy persons. Am. J. Trop. Med. Hyg. 83, 1195-1201 (2010
125. Peters P. J., Thigpen M. C., Parise M. E. & Newman R. D. Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug Saf. 30, 481-501 (2007
126. Meremikwu M. M., Donegan S., Sinclair D., Esu E. & Oringanje C. Intermittent preventive treatment for malaria in children living in areas with seasonal transmission. Cochrane Database Syst. Rev. 2, CD003756 (2012
127. Bueno J. M., et al. Exploration of 4(1H)-pyridones as a novel family of potent antimalarial inhibitors of the plasmodial cytochrome bc1. Future Med. Chem. 4, 2311-2323 (2012
128. Capper M. J., et al. Antimalarial 4(1H)-pyridones bind to the Qi site of cytochrome bc1. Proc. Natl Acad. Sci. USA 112, 755-760 (2015
129. Powles M. A., et al. MK 4815, a potential new oral agent for treatment of malaria. Antimicrob. Agents Chemother. 56, 2414-2419 (2012
130. Macareo L., et al. Triangular test design to evaluate tinidazole in the prevention of Plasmodium vivax relapse. Malar. J. 12, 173 (2013
131. Bousejra El Garah F., Claparols C., Benoit-Vical F., Meunier B. & Robert A. The antimalarial trioxaquine DU1301 alkylates heme in malaria-infected mice. Antimicrob. Agents Chemother. 52, 2966-2969 (2008
132. Dwivedi A., et al. Role of type II pathway in apoptotic cell death induction by photosensitized CDRI 97/78 under ambient exposure of UV B. Toxicol. Lett. 222, 122-131 (2013
133. Kushwaha H. N., et al. Intersex effect of lamotrigine on the pharmacokinetic parameters of CDRI 97/78, a novel trioxane antimalarial compound, in rats. Arzneimittelforschung 62, 274-279 (2012
134. Kushwaha H. N., et al. Effect of carbamazepine on the pharmacokinetic parameters of CDRI 97/78 following coadministration to rats. Drug Res. (Stuttg.) 63, 282-288 (2013
135. Shafiq N., et al. Single ascending dose safety and pharmacokinetics of CDRI 97/78: first in human study of a novel antimalarial drug. Malar. Res. Treat. 2014, 372521 (2014
136. Mombo-Ngoma G., et al. Phase I randomized dose-ascending placebo-controlled trials of ferroquine -a candidate anti-malarial drug -in adults with asymptomatic Plasmodium falciparum infection. Malar. J. 10, 53 (2011
137. Lanaspa M., et al. Inadequate efficacy of a new formulation of fosmidomycin-clindamycin combination in Mozambican children less than three years old with uncomplicated Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 56, 2923-2928 (2012
138. Lakshminarayana S. B., et al. Pharmacokinetics-pharmacodynamics analysis of spiroindolone analogs and KAE609 in a murine malaria model. Antimicrob. Agents Chemother. 59, 1200-1210 (2014
139. Kuhen K. L., et al. KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment and prevention of disease transmission. Antimicrob. Agents Chemother. 58, 5060-5067 (2014
140. Guttmann P. & Ehrlich P. Über die wirkung des methylenblau bei malaria. Berliner Klinische Wochenschrift 28, 953-956 (in German) (1891
141. Coulibaly B., et al. Efficacy and safety of triple combination therapy with artesunate-amodiaquine-methylene blue for falciparum malaria in children: a randomized controlled trial in Burkina Faso. J. Infect. Dis. 211, 689-687 (2014
142. Ciana C. L., et al. Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold. Bioorg. Med. Chem. Lett. 23, 658-662 (2013
143. Bruderer S., et al. First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT 451840, a new chemical entity with antimalarial activity. Antimicrob. Agents Chemother. 59, 935-942 (2015
144. Nanayakkara N. P., et al. Antiparasitic activities and toxicities of individual enantiomers of the 8 aminoquinoline 8-[(4 amino 1 methylbutyl)amino]-6 methoxy 4 methyl 5-[3,4 dichlorophenoxy] quinoline succinate. Antimicrob. Agents Chemother. 52, 2130-2137 (2008
145. Marcsisin S. R., et al. Tafenoquine and NPC 1161B require CYP2D metabolism for anti-malarial activity: implications for the 8 aminoquinoline class of anti-malarial compounds. Malar. J. 13, 2 (2014
146. Marti F., et al. Second generation analogues of RKA182: synthetic tetraoxanes with outstanding in vitro and in vivo antimalarial activities. MedChemComm 2, 661-665 (2011
147. Copple I. M., et al. Examination of the cytotoxic and embryotoxic potential and underlying mechanisms of next-generation synthetic trioxolane and tetraoxane antimalarials. Mol. Med. 18, 1045-1055 (2012
148. Yuthavong Y., et al. Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc. Natl Acad. Sci. USA 109, 16823-16828 (2012
149. Jomaa H., et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 285, 1573-1576 (1999
150. Deng X., et al. Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors. J. Med. Chem. 57, 5381-5394 (2014
151. da Cruz F. P., et al. Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug. J. Infect. Dis. 205, 1278-1286 (2012
152. Nam T. G., et al. A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor. ACS Chem. Biol. 6, 1214-1222 (2011
153. Wang J., Kaiser M. & Copp B. R. Investigation of indolglyoxamide and indolacetamide analogues of polyamines as antimalarial and antitrypanosomal agents. Mar. Drugs 12, 3138-3160 (2014
154. Salas-Sarduy E., et al. Antiparasitic effect of a fraction enriched in tight-binding protease inhibitors isolated from the Caribbean coral Plexaura homomalla. Exp. Parasitol. 135, 611-622 (2013
155. Hansen F. K., et al. Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages. Eur. J. Med. Chem. 82, 204-213 (2014
156. Trenholme K., et al. Lysine acetylation in sexual stage malaria parasites is a target for antimalarial small molecules. Antimicrob. Agents Chemother. 58, 3666-3678 (2014
157. Sumanadasa S. D., et al. Antimalarial activity of the anticancer histone deacetylase inhibitor SB939. Antimicrob. Agents Chemother. 56, 3849-3856 (2012
158. Jaudzems K., et al. Plasmepsin inhibitory activity and structure-guided optimization of a potent hydroxyethylamine-based antimalarial hit. ACS Med. Chem. Lett. 5, 373-377 (2014
159. Meyers M. J., et al. Evaluation of aminohydantoins as a novel class of antimalarial agents. ACS Med. Chem. Lett. 5, 89-93 (2014
160. McCarthy J. S., et al. A Phase I/Ib study to investigate the safety, tolerability and pharmacokinetic profile of DSM265 in healthy subjects and then its antimalarial activity in induced blood stage Plasmodium falciparum infection. ASTMH Ann. Meeting Abstr. 675, 204-205 (2014